Loading...
XNAS
PSTV
Market cap9mUSD
Jul 09, Last price  
4.00USD
1D
4.71%
1Q
-16.67%
Jan 2017
-100.00%
IPO
-100.00%
Name

Plus Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:PSTV chart
P/E
—
P/S
1.86
EPS
—
Div Yield, %
—
Shrs. gr., 5y
142.27%
Rev. gr., 5y
76.66%
Revenues
5m
-10.49%
7,927,0006,049,0006,853,00014,730,00010,627,0009,996,00014,501,00012,196,0007,598,00011,659,00011,380,0006,411,0002,983,0006,998,000303,0000224,0004,913,0005,824,0005,213,000
Net income
-22m
L+72.49%
-25,447,000-28,672,000-30,036,000-23,216,000-27,494,000-32,451,000-32,279,000-26,177,000-37,368,000-18,744,000-22,046,000-22,686,000-12,634,000-10,887,000-8,241,000-13,399,000-20,275,000-13,316,000-12,978,000-22,386,000
CFO
-21m
L+96.84%
-16,483,000-29,995,000-33,389,000-23,807,000-23,574,000-35,323,000-32,193,000-34,563,000-30,330,000-20,468,000-19,533,000-18,128,000-11,975,000-5,906,000-8,434,000-10,280,000-12,972,000-12,851,000-10,554,000-20,775,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Plus Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, dedicated to the development, manufacturing, and market introduction of therapeutic solutions for cancer patients and individuals with other serious illnesses. A cornerstone of their pipeline is Rhenium-186 NanoLiposome (R-186 NL), a patented radiotherapy specifically engineered to address difficult central nervous system (CNS) cancers, such as recurrent glioblastoma, leptomeningeal metastases, and various brain cancers affecting children. The company has also secured a licensing agreement with NanoTx, Corp. to advance and commercialize NanoTx's treatment for glioblastoma. Founded in 1996 and headquartered in Austin, Texas, the firm adopted its current name, Plus Therapeutics, Inc., in July 2019, having previously operated as Cytori Therapeutics, Inc.
URL
http://www.plustherapeutics.com/
IPO date
Aug 09, 2000
Employees
17
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT